This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
Food and Drug Administration, HHS.
Notification of withdrawal.
The Food and Drug Administration (FDA) is withdrawing approval of 18 new animal drug applications (NADAs) and 2 abbreviated new animal drug applications (ANADAs). These withdrawals of approval of NADAs and ANADAs for antimicrobial drugs of importance to human medicine that are administered to food-producing animals in medicated feed are being made because the products are no longer manufactured or marketed. These actions are consistent with the FDA Center for Veterinary Medicine's initiative for the Judicious Use of Antimicrobials.
Withdrawal of approval is effective February 24, 2017.
Sujaya Dessai, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-402-5761, sujaya.dessai@fda.hhs.gov.
FDA is withdrawing approval of 18 NADAs and 2 ANADAs. These applications were identified as being affected by guidance for industry (GFI) #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions With GFI #209,” December 2013 ( http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM299624.pdf). Their withdrawal of approval is consistent with the FDA Center for Veterinary Medicine's initiative for the Judicious Use of Antimicrobials.
Approval of the following applications for new animal drugs administered in medicated feed is being voluntarily withdrawn at the sponsors' requests because these products are no longer manufactured or marketed:
| File No. | Product name | Sponsor |
|---|---|---|
| 044-820 | LINCOMIX (lincomycin)/AMPROL PLUS (amprolium and ethopabate) | Zoetis Inc. 333 Portage St. Kalamazoo, MI 49007 (Zoetis Inc.). |
| ( printed page 11510) | ||
| 044-972 | LINCOMIX (lincomycin)/COYDEN (clopidol) | Zoetis Inc. |
| 047-261 | LINCOMIX (lincomycin)/DECCOX (decoquinate) | Zoetis Inc. |
| 047-262 | LINCOMIX (lincomycin)/DECCOX (decoquinate) | Zoetis Inc. |
| 048-954 | LINCOMIX (lincomycin)/ZOAMIX (zoalene) | Zoetis Inc. |
| 091-513 | STAFAC (virginiamycin) Type A Medicated Article | Phibro Animal Health Corp., GlenPointe Centre East, 3d floor, 300 Frank W. Burr Blvd., Suite 21, Teaneck, NJ 07666 (Phibro Animal Health Corp.). |
| 092-482 | LINCOMIX (lincomycin)/COBAN (monensin) | Zoetis Inc. |
| 093-106 | LINCOMIX (lincomycin)/ROBENZ (robenidine) | Zoetis Inc. |
| 101-689 | LINCOMIX (lincomycin)/AVATEC (lasalocid) | Zoetis Inc. |
| 122-481 | STAFAC (virginiamycin)/COBAN (monensin) | Phibro Animal Health Corp. |
| 122-608 | STAFAC (virginiamycin)/AVATEC (lasalocid) | Phibro Animal Health Corp. |
| 122-822 | STAFAC (virginiamycin)/AMPROL PLUS (amprolium and ethopabate) | Phibro Animal Health Corp. |
| 137-537 | LINCOMIX (lincomycin)/BIO-COX (salinomycin) | Zoetis Inc. |
| 138-792 | TYLAN (tylosin)/RUMENSIN (monensin)/MGA (melengestrol acetate) | Zoetis Inc. |
| 138-828 | STAFAC (virginiamycin)/BIO-COX (salinomycin) | Phibro Animal Health Corp. |
| 138-904 | TYLAN (tylosin)/BOVATEC (lasalocid)/MGA (melengestrol acetate) | Zoetis Inc. |
| 141-110 | STAFAC (virginiamycin)/COBAN (monensin) | Phibro Animal Health Corp. |
| 141-150 | STAFAC (virginiamycin)/AVATEC (lasalocid) | Phibro Animal Health Corp. |
| 200-092 | STAFAC (virginiamycin)/SACOX (salinomycin) | Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria (Huvepharma EOOD). |
| 200-093 | LINCOMIX (lincomycin)/SACOX (salinomycin) | Huvepharma EOOD. |
Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 Notice of withdrawal of approval of application (21 CFR 514.116), notice is given that approval of NADAs 044-820, 044-972, 047-261, 047-262, 048-954, 091-513, 092-482, 093-106, 101-689, 122-481, 122-608, 122-822, 137-537, 138-792, 138-828, 138-904, 141-110, 141-150, 200-092, and 200-093, and all supplements and amendments thereto, is hereby withdrawn, effective February 24, 2017.
Elsewhere in this issue of the Federal Register , FDA is amending the animal drug regulations to reflect the voluntary withdrawal of approval of these applications.
Dated: February 17, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-03595 Filed 2-23-17; 8:45 am]
BILLING CODE 4164-01-P